Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC) MIPLYFFA(TM) becomes 6th commercial asset in XOMA Royalty's portfolio

Orphazyme announces US Early Access Program for Niemann-Pick disease Type C Orphazyme A/SCompany announcement                                                                                       No....